CN Patent

CN104918945B — 作为jak抑制剂的三环稠合噻吩衍生物

Assigned to Incyte Corp · Expires 2018-01-05 · 8y expired

What this patent protects

本发明提供三环稠合噻吩衍生物以及其组合物和使用方法，所述三环稠合噻吩衍生物调节Janus激酶(JAK)活性且适用于治疗与JAK活性相关的疾病，包括例如炎症性病症、自体免疫性病症、癌症和其它疾病。

USPTO Abstract

本发明提供三环稠合噻吩衍生物以及其组合物和使用方法，所述三环稠合噻吩衍生物调节Janus激酶(JAK)活性且适用于治疗与JAK活性相关的疾病，包括例如炎症性病症、自体免疫性病症、癌症和其它疾病。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN104918945B
Jurisdiction: CN
Classification: —
Expires: 2018-01-05
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.